1. Home
  2. WST vs UTHR Comparison

WST vs UTHR Comparison

Compare WST & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • UTHR
  • Stock Information
  • Founded
  • WST 1923
  • UTHR 1996
  • Country
  • WST United States
  • UTHR United States
  • Employees
  • WST N/A
  • UTHR N/A
  • Industry
  • WST Medical/Dental Instruments
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • WST Health Care
  • UTHR Health Care
  • Exchange
  • WST Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • WST 20.1B
  • UTHR 20.7B
  • IPO Year
  • WST N/A
  • UTHR 1999
  • Fundamental
  • Price
  • WST $299.62
  • UTHR $422.12
  • Analyst Decision
  • WST Strong Buy
  • UTHR Buy
  • Analyst Count
  • WST 8
  • UTHR 15
  • Target Price
  • WST $348.00
  • UTHR $466.73
  • AVG Volume (30 Days)
  • WST 707.3K
  • UTHR 654.5K
  • Earning Date
  • WST 10-23-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • WST 0.30%
  • UTHR N/A
  • EPS Growth
  • WST 0.17
  • UTHR 17.94
  • EPS
  • WST 6.75
  • UTHR 25.63
  • Revenue
  • WST $3,017,900,000.00
  • UTHR $3,077,800,000.00
  • Revenue This Year
  • WST $6.49
  • UTHR $13.82
  • Revenue Next Year
  • WST $6.23
  • UTHR $5.71
  • P/E Ratio
  • WST $44.06
  • UTHR $16.33
  • Revenue Growth
  • WST 4.92
  • UTHR 17.62
  • 52 Week Low
  • WST $187.43
  • UTHR $266.98
  • 52 Week High
  • WST $352.33
  • UTHR $459.48
  • Technical
  • Relative Strength Index (RSI)
  • WST 72.87
  • UTHR 49.32
  • Support Level
  • WST $260.12
  • UTHR $419.47
  • Resistance Level
  • WST $322.34
  • UTHR $436.00
  • Average True Range (ATR)
  • WST 7.39
  • UTHR 9.35
  • MACD
  • WST 3.28
  • UTHR -5.56
  • Stochastic Oscillator
  • WST 64.97
  • UTHR 6.64

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: